AbbVie received FDA approval for a first in class, all oral, fixed duration regimen combining VENCLEXTA and acalabrutinib for previously untreated chronic lymphocytic leukemia. The company announced a ...
The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.
A newly approved combination of acalabrutinib plus venetoclax gives with newly diagnosed chronic lymphocytic leukemia (CLL) another chemotherapy-free option that is taken for a fixed period of time ...
The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and ...
Mitochondrial DNA heteroplasmy is independently associated with an increased risk of CLL, suggesting potential as a novel biomarker for early risk identification.
FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...
AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...
Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...
Two years after premiering a 13-minute documentary about three eczema patients, Abbvie has again teamed with branded entertainment firm Passion Point Collective, this time for a 16-minute documentary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results